Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07800572 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Anisodine Hydrobromide for Patients With Acute Ischemic Stroke Undergoing Endovascular Therapy (HEAL-2)

StatusRecruiting
PhasePhase 2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Study sites: 11 to 13
  2. Recruitment opened
    • Start date changed from estimate of Aug 31, 2026 to Sep 6, 2026
    • Site details revised at 11 of 11 sites
  3. Secondary endpoints: details revised at 7 of 8 entries
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase 2, multicenter, randomized, double-blind, placebo-controlled trial will evaluate the efficacy and safety of anisodine hydrobromide in patients with acute ischemic stroke undergoing endovascular thrombectomy.
Trial Details
NCT Number NCT07800572
Lead Sponsor Capital Medical University
Conditions
(from sponsor)		 Acute Ischemic Stroke
Related terms Ischemic Stroke, Stroke
Enrollment 204 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov